Considering the demonstrated benefit of EGFR inhibition in EGFR-mutated advanced NSCLC and the prevalence of MET dysregulation in resistance to third generation EGFR inhibitors, inhibition of EGFR and MET in combination has been a preferred strategy in clinical investigation in patients previously treated and progressed after initial EGFR inhibitor therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.